Mark Auerbach - 23 Dec 2021 Form 4 Insider Report for PARDES BIOSCIENCES, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 23 Dec 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Dec 2021, 15:30:24 UTC
Next SEC filing: 10 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Lacy, attorney-in-fact

Key filing fact

Mark Auerbach filed Form 4 for PARDES BIOSCIENCES, INC. on 28 Dec 2021.

Key facts

This page summarizes Mark Auerbach's Form 4 filing for PARDES BIOSCIENCES, INC..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Dec 2021, 15:30.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRDS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +75,000
Change %
Price: $0.000000
Shares after: 75,000
Date: 23 Dec 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,000
Exercise price: $9.80
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option shall vest in substantially equal monthly installments over three years, subject to a continued service relationship. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2021 Stock Option and Incentive Plan with the U.S. Securities and Exchange Commission.